One of These Things Is Not Like the Others: The Idea of Precedence in Health Technology Assessment and Coverage Decisions

June 2005 in “ The Milbank Quarterly ”

Mita Giacomini

intracytoplasmic sperm injection genetic tests BRCA1 BRCA2 sildenafil Viagra ICSI

Studysummary This article describes a framework for evaluating new health technologies by integrating quantitative evidence with qualitative assessments and using precedents to guide policy decisions, without reporting new clinical results.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research Case Study: Hereditary Cancer Genetic Testing in Unaffected Patients May Allow for Early Intervention and Aggressive Management

October 2014 in “Journal of Minimally Invasive Gynecology”

Genetic testing for cancer risk can lead to early and life-saving treatments in people without symptoms.

research Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers

10 citations , February 2022 in “Cancers”

This review discusses managing prostate cancer in patients with high-risk germline mutations and highlights the need for more research and consensus guidelines, reporting no new clinical results.

research Insurers Give Short Shrift to ASCO Pathways Recommendation

March 2016 in “Oncology Times”

This article reviews the challenges and differing perspectives on implementing cancer care pathways, highlighting an ASCO task force's recommendation for flexibility that met resistance due to administrative burdens and regional variations.

research Re‐Innovation in Clinical Trial Designs Based on Precision Therapy

September 2025 in “Cancer Innovation”

This study argues for "clinical trial re-innovation," highlighting new designs like basket, umbrella, and platform trials that incorporate biomarker technologies to meet the dynamic needs of precision medicine, potentially enabling more effective, patient-specific treatments and overcoming limitations of traditional disease-centered trials.

research The Current Landscape for Direct-to-Consumer Genetic Testing: Legal, Ethical, and Policy Issues

244 citations , September 2008 in “Annual Review of Genomics and Human Genetics”

This review examines the direct-to-consumer genetic testing market, highlighting the available tests, regulatory issues, and calls for increased oversight, and reports no new results.